摘要:
The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
摘要:
Provided herein are glucagon superfamily peptides conjugated with GR ligands that are capable of acting at a glucocorticoid receptor. Also provided herein are pharmaceutical compositions and kits of the conjugates of the invention. Further provided herein are methods of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the conjugates of the invention.
摘要:
The present invention provides uses of TRPV4 antagonists in the treatment or prevention of hydrocephalus symptoms, also known as hydrocephaly, including hydrocephalus as a result of any structural defect, any metabolic defect, any injury (direct force to the head, indirect force to the head, shock waves, pressure changes, etc.), any insult (microbial, chemical, toxins, allergic reactions or other inflammatory process, or other pathology, eg. cancer, benign tumor, etc.). Related materials and methods are also provided herein.
摘要:
A method of extending the life of a battery, including positioning a dendrite seeding material in an electrolyte solution disposed between a metal-containing electrode and an electrolyte permeable separator membrane, growing metal dendrites from the lithium dendrite seeding material toward the lithium-containing electrode, and contacting metal dendrites extending from the metal containing electrode with metal dendrites extending from the metal dendrite seeding material, wherein the electrolyte contains metal ions.
摘要:
Described herein are methods for identifying compounds useful for the treatment of infection by hepatitis B virus (HBV) and for identifying compounds useful for the same.
摘要:
Prodrug formulations of glucagon superfamily peptides are provided wherein the glucagon superfamily peptide has been modified by the linkage of a dipeptide to the glucagon superfamily through an amide bond linkage. The prodrugs disclosed herein have extended half lives and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability.